Toll-like receptor 2-modulating pectin-polymers in alginate-based microcapsules attenuate immune responses and support islet-xenograft survival
Shuxian Hu,Rei Kuwabara,Carlos E Navarro Chica,Alexandra M Smink,Taco Koster,Juan D Medina,Bart J de Haan,Martin Beukema,Jonathan R T Lakey,Andrés J García,Paul de Vos,Carlos E. Navarro Chica,Alexandra M. Smink,Juan D. Medina,Bart J. de Haan,Jonathan R.T. Lakey,Andrés J. García
DOI: https://doi.org/10.1016/j.biomaterials.2020.120460
IF: 14
2021-01-01
Biomaterials
Abstract:<p>Encapsulation of pancreatic islets in alginate-microcapsules is used to reduce or avoid the application of life-long immunosuppression in preventing rejection. Long-term graft function, however, is limited due to varying degrees of host tissue responses against the capsules. Major graft-longevity limiting responses include inflammatory responses provoked by biomaterials and islet-derived danger-associated molecular patterns (DAMPs). This paper reports on a novel strategy for engineering alginate microcapsules presenting immunomodulatory polymer pectin with varying degrees of methyl-esterification (DM) to reduce these host tissue responses. DM18-pectin/alginate microcapsules show a significant decrease of DAMP-induced Toll-Like Receptor-2 mediated immune activation <em>in vitro</em>, and reduce peri-capsular fibrosis <em>in vivo</em> in mice compared to higher DM-pectin/alginate microcapsules and conventional alginate microcapsules. By testing efficacy of DM18-pectin/alginate microcapsules <em>in vivo</em>, we demonstrate that low-DM pectin support long-term survival of xenotransplanted rat islets in diabetic mice. This study provides a novel strategy to attenuate host responses by creating immunomodulatory capsule surfaces that attenuate activation of specific pro-inflammatory immune receptors locally at the transplantation site.</p>
engineering, biomedical,materials science, biomaterials